Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer

NCT00045188 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer

Interventions

DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)